Cabazitaxel in patients aged ≥80 years with castration-resistant prostate cancer: Results of a post-marketing surveillance study in Japan.
Cabazitaxel
Castration-resistant prostate cancer
Geriatric oncology
Post-marketing drug surveillance
Journal
Journal of geriatric oncology
ISSN: 1879-4076
Titre abrégé: J Geriatr Oncol
Pays: Netherlands
ID NLM: 101534770
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
29
10
2019
revised:
23
01
2020
accepted:
26
02
2020
pubmed:
22
3
2020
medline:
29
7
2021
entrez:
22
3
2020
Statut:
ppublish
Résumé
Data on the safety and efficacy of cabazitaxel in patients aged ≥80 years with castration-resistant prostate cancer (CRPC) are limited. We report the safety (adverse drug reactions [ADRs]) and efficacy (overall survival [OS], time to treatment failure [TTF], and prostate-specific antigen [PSA] response rates) in patients aged <80 or ≥80 years treated with cabazitaxel for CRPC in clinical practice. We performed post-hoc subgroup analyses of a Japanese post-marketing surveillance study involving 662 patients with CRPC treated with cabazitaxel between September 2014 and June 2016. In patients aged <80 (n = 610) and ≥80 years (n = 49), median PSA at baseline was 168.7 and 109.0 ng/mL, and 86.7% and 83.7% of patients were previously treated with enzalutamide and/or abiraterone. ADRs (all grade) occurred in 77.2% and 79.6% of patients aged <80 and ≥80 years, with grade three/worse ADRs in 61.8% and 63.3% of patients. Hematologic toxicities were the most common grade three/worse ADRs, including neutropenia, febrile neutropenia, and anemia in both subgroups. No specific ADRs were observed in patients aged ≥80 years. The PSA response and median OS and TTF were 28.3%, 292 days, and 116 days in patients aged ≥80 years, and 29.7%, 319 days, and 125 days in patients aged <80 years. Cabazitaxel could be a treatment option for CRPC in patients aged ≥80 years based on its safety and efficacy profiles. This is the first report to investigate the safety and efficacy of cabazitaxel in patients aged ≥80 years with CRPC.
Identifiants
pubmed: 32198082
pii: S1879-4068(19)30502-8
doi: 10.1016/j.jgo.2020.02.014
pii:
doi:
Substances chimiques
Taxoids
0
cabazitaxel
51F690397J
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1067-1073Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest Nobuaki Matsubara has received personal fees from Janssen, MSD, AstraZeneca, and Sanofi, and research grants from Janssen, MSD, Roche, Lilly, Taiho, BMS, and AstraZeneca. Hideyasu Matsuyama has served on an advisory board for Sanofi. Kazuhiro Suzuki has received personal fees from Sanofi, Takeda, Astellas, AstraZeneca, Janssen, Daiichi-Sankyo, Chugai, Kyowa-Kirin, and Bayer, and research grants from Takeda, Astellas, AstraZeneca, Daiichi-Sankyo, Chugai, Kyowa-Kirin, and Bayer. Hirotaka Kazama, Shoko Tsukube, and Takeshi Seto are employees of Sanofi.